1637. Safety Evaluation of the Novel Oral Polio Vaccine Type 2 during a National Supplementary Immunisation Activity in Uganda, a Multipronged Approach: January–March 2022

BACKGROUND: Data from clinical trials show that novel oral poliovirus vaccine type 2 (nOPV2) is safe. However, nOPV2 is under emergency use listing, and continued vaccine safety monitoring is required to support licensure and World Health Organization (WHO) prequalification. In January 2022, Uganda...

Descripción completa

Detalles Bibliográficos
Autores principales: Nsubuga, Fred, Gilani, Zunera, Tobolowsky, Farrell A, Longley, Ashley T, Greene, Sharon A, Ntale, Ismail, Hellen, Ndagije, Kisakye, Annet, Ampaire, Immaculate, Kyabayinze, Daniel, Gidudu, Jane F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677646/
http://dx.doi.org/10.1093/ofid/ofad500.1471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677646/
http://dx.doi.org/10.1093/ofid/ofad500.1471

Ejemplares similares